← Leaderboards
Catherine Choy Smith
University Of California, San Francisco
$4,365,274
Attributed
$4,365,274
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,365,274 · 3
By mechanism
R01$3,662,042 · 2
K08$703,232 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Neil P Shah$6,146,823
- Sabrina Miriam Ronen$18,398,578
- Michael T McManus$36,428,993
- Trever G Bivona$22,714,857
- Jayanta Debnath$11,943,792
Others in their field
Top investigators on “American”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Antonio J Busalacchi · University Of Maryland, College Park$243,972,016
- Everette D Joseph · Howard University$243,972,016
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Eric J Barron · Pennsylvania State Univ University Park$243,972,016
- Ethan Schreier · Associated Universities, Inc.$207,732,557
Research focus
AmericanRelapseTyrosine Kinase InhibitorAffectSignal TransductionGenesCombined Modality TherapyResistanceMutationResponseMediatingClinical TrialsResistance MechanismOncogenicAcute Myelocytic LeukemiaMutateTranslatingPhosphotransferasesSamplingMalignant NeoplasmsNovel TherapeuticsInhibitorInhibitor TherapyBcl2 Gene
Grant awards (13)
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation$547,180
R01 · FY2025 · CA · contact PI
Investigating the mechanism of SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia (AML)$456,661
R01 · FY2025 · CA · contact PI
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation$77,113
R01 · FY2025 · CA · contact PI
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation$523,510
R01 · FY2024 · CA · contact PI
Investigating the mechanism of SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia (AML)$482,061
R01 · FY2024 · CA · contact PI
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation$77,113
R01 · FY2024 · CA · contact PI
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation$534,924
R01 · FY2023 · CA · contact PI
Investigating the mechanism of SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia (AML)$412,854
R01 · FY2023 · CA · contact PI
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation$550,626
R01 · FY2022 · CA · contact PI
Investigating Resistance to FLT3 Inhibitors in AML$175,808
K08 · FY2017 · CA · contact PI
Investigating Resistance to FLT3 Inhibitors in AML$175,808
K08 · FY2016 · CA · contact PI
Investigating Resistance to FLT3 Inhibitors in AML$175,808
K08 · FY2015 · CA · contact PI
Investigating Resistance to FLT3 Inhibitors in AML$175,808
K08 · FY2014 · CA · contact PI